TKCBY yields 3.01% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, TKCBY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TKCBY + PFE for your $10,000?
Tokai Carbon Co., Ltd. manufactures and sells carbon-related products and services in Japan. It offers graphite electrodes for use in electric furnaces, such as direct current, alternating current, and refining furnaces; and carbon black, including SEAST, TOKABLACK, Aqua Black, and Thermal black varieties, which are used to reinforce the rubber in tires, as well as used as a black pigment in various black-colored products. It also provides fine carbon products comprising special graphite products that include isotropic graphite G/HK series, extruded graphite, SiC coated carbon, C/C composite, glassy carbon, solid SiC, carbon brush, and resin-impregnated graphite products, as well as furnace materials for silicon semiconductor, solar cell manufacturing, and other applications; and industrial furnaces and related products, which comprise silicon carbide heating elements, resistors, recryte SiC structural materials, and industrial furnaces for heat treatment of ceramics, electronic components, metals, glass, and others. In addition, it provides carbon and graphite products and solutions for various smelting applications; and friction materials, including sintered metal friction, paper friction, carbonaceous friction, sliding, resin, woven, and soft mold materials to regulate power transmission in industrial and construction machinery, as well as for use in brake and clutch parts of vehicles, such as motorbikes, trucks, buses, and trains. Further, the company offers anode materials for secondary lithium-ion batteries that are used in smartphones and electric cars. The company was formerly known as Tokai Electrode Mfg. Co. Ltd. and changed its name to Tokai Carbon Co., Ltd. in 1975. Tokai Carbon Co., Ltd. was founded in 1918 and is headquartered in Tokyo, Japan.
Full TKCBY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.